FI892131A0 - Analoger till underenheter av bordetellatoxin, vilka haerstammar fraon hybrid-dna. - Google Patents

Analoger till underenheter av bordetellatoxin, vilka haerstammar fraon hybrid-dna.

Info

Publication number
FI892131A0
FI892131A0 FI892131A FI892131A FI892131A0 FI 892131 A0 FI892131 A0 FI 892131A0 FI 892131 A FI892131 A FI 892131A FI 892131 A FI892131 A FI 892131A FI 892131 A0 FI892131 A0 FI 892131A0
Authority
FI
Finland
Prior art keywords
underenheter
haerstammar
bordetellatoxin
analoger
vilka
Prior art date
Application number
FI892131A
Other languages
English (en)
Other versions
FI101632B (fi
FI101632B1 (fi
FI892131A (fi
Inventor
Iii Walter Neal Burnette
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26788722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI892131(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of FI892131A publication Critical patent/FI892131A/fi
Publication of FI892131A0 publication Critical patent/FI892131A0/fi
Application granted granted Critical
Publication of FI101632B publication Critical patent/FI101632B/fi
Publication of FI101632B1 publication Critical patent/FI101632B1/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
FI892131A 1987-09-04 1989-05-03 Menetelmä Bordetella pertussis-toksiinin alayksikön analogien valmistamiseksi ja niitä koodaavia rekombinantti-DNA-molekyylejä FI101632B1 (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US9430787A 1987-09-04 1987-09-04
US9430787 1987-09-04
US23248288A 1988-08-17 1988-08-17
US23248288 1988-08-17
PCT/US1988/002983 WO1989001976A1 (en) 1987-09-04 1988-08-26 Recombinant dna-derived bordetella toxin subunit analogs
US8802983 1988-08-26

Publications (4)

Publication Number Publication Date
FI892131A FI892131A (fi) 1989-05-03
FI892131A0 true FI892131A0 (fi) 1989-05-03
FI101632B FI101632B (fi) 1998-07-31
FI101632B1 FI101632B1 (fi) 1998-07-31

Family

ID=26788722

Family Applications (1)

Application Number Title Priority Date Filing Date
FI892131A FI101632B1 (fi) 1987-09-04 1989-05-03 Menetelmä Bordetella pertussis-toksiinin alayksikön analogien valmistamiseksi ja niitä koodaavia rekombinantti-DNA-molekyylejä

Country Status (16)

Country Link
US (1) US5773600A (fi)
EP (2) EP0306318B2 (fi)
JP (1) JP2918895B2 (fi)
KR (1) KR0168039B1 (fi)
CN (1) CN1033866C (fi)
AT (1) ATE125568T1 (fi)
CA (1) CA1341560C (fi)
DE (1) DE3854213T3 (fi)
DK (1) DK175821B1 (fi)
ES (1) ES2076160T5 (fi)
FI (1) FI101632B1 (fi)
GR (1) GR3017497T3 (fi)
IE (1) IE69753B1 (fi)
IL (3) IL87608A0 (fi)
NO (2) NO301844B1 (fi)
WO (1) WO1989001976A1 (fi)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925546A (en) * 1987-11-02 1999-07-20 Chiron S.P.A. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
US6713072B1 (en) * 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
IT1223334B (it) * 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
US5332583A (en) * 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5358868A (en) * 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
CA2009991A1 (en) * 1989-02-15 1990-08-15 Witold Cieplak Pertussis toxin gene: cloning and expression of protective antigen
US7232671B2 (en) * 1989-02-15 2007-06-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
EP0396964B1 (en) * 1989-04-28 1995-09-06 SCLAVO S.p.A. Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines
US5786189A (en) * 1989-11-29 1998-07-28 Smithkline Beecham Biologicals (S.A.) Vaccine
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) * 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
EP1234580A1 (en) * 1995-05-04 2002-08-28 Aventis Pasteur Limited Acellular Pertussis Vaccines and Methods of Preparation Thereof
WO1997043407A1 (en) * 1996-05-10 1997-11-20 Phylomed Corporation Methods for oxidizing disulfide bonds using ozone
FR2754543B1 (fr) * 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2574953A1 (en) 2004-07-26 2006-02-09 Dow Global Technolgies Inc. Process for improved protein expression by strain engineering
CA2590906C (en) * 2004-12-17 2017-01-03 Nvi Nederlands Vaccininstituut Deacylation of lps in gram negative bacteria
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2008134461A2 (en) 2007-04-27 2008-11-06 Dow Global Technologies, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
MX343356B (es) 2010-03-30 2016-11-03 Pfenex Inc * Toxinas proteicas recombinantes de alto nivel de expresion.
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
MX362793B (es) 2013-03-08 2019-02-13 Janssen Vaccines & Prevention Bv Vacuna acelular contra pertussis.
BE1022008B1 (fr) 2013-08-05 2016-02-03 Glaxosmithkline Biologicals S.A. Compositions immunogenes combinees
CN109172818B (zh) * 2018-08-02 2021-10-22 浙江康佰裕生物科技有限公司 一种蛋白牛痘疫苗及其效力检测方法
US20220047690A1 (en) * 2018-10-15 2022-02-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Vaccine polypeptide compositions and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
FR2590483B1 (fr) * 1985-11-22 1988-12-09 Pasteur Institut Antigenes purifies ayant des proprietes vaccinantes contre b. pertussis, moyens notamment adns recombinants pour les produire et compositions de vaccins les contenant
CA1340373C (en) * 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
EP0275689B1 (en) * 1986-12-23 1992-09-02 The Board Of Trustees Of The Leland Stanford Junior University Modified pertussis exotoxin
IT1223334B (it) * 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
IT1223529B (it) * 1987-12-18 1990-09-19 Sclavo Spa Epitopo immunodominante protettivo contenuto nella subunita' s1 della tossina della pertosse

Also Published As

Publication number Publication date
FI101632B (fi) 1998-07-31
KR890701758A (ko) 1989-12-21
IE69753B1 (en) 1996-10-02
EP0306318B2 (en) 2004-04-28
CN1033866C (zh) 1997-01-22
JP2918895B2 (ja) 1999-07-12
AU623867B2 (en) 1992-05-28
NO301844B1 (no) 1997-12-15
JPH04501051A (ja) 1992-02-27
NO972642L (no) 1997-07-28
IL87608A0 (en) 1989-01-31
FI101632B1 (fi) 1998-07-31
NO972642D0 (no) 1997-06-09
NO325016B1 (no) 2008-01-14
NO891842L (no) 1989-06-21
IL103121A (en) 1995-08-31
CN1033072A (zh) 1989-05-24
IL103121A0 (en) 1993-02-21
EP0306318B1 (en) 1995-07-26
NO891842D0 (no) 1989-05-03
EP0629696A1 (en) 1994-12-21
KR0168039B1 (ko) 1999-01-15
DE3854213T2 (de) 1995-12-07
DE3854213D1 (de) 1995-08-31
FI892131A (fi) 1989-05-03
CA1341560C (en) 2007-10-30
ATE125568T1 (de) 1995-08-15
DE3854213T3 (de) 2004-10-21
DK216289D0 (da) 1989-05-03
WO1989001976A1 (en) 1989-03-09
US5773600A (en) 1998-06-30
EP0306318A1 (en) 1989-03-08
AU2386488A (en) 1989-03-31
DK175821B1 (da) 2005-03-14
GR3017497T3 (en) 1995-12-31
ES2076160T3 (es) 1995-11-01
ES2076160T5 (es) 2004-12-01
IE882668L (en) 1989-03-04
DK216289A (da) 1989-06-30

Similar Documents

Publication Publication Date Title
FI892131A0 (fi) Analoger till underenheter av bordetellatoxin, vilka haerstammar fraon hybrid-dna.
MX9203458A (es) Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano.
ES2156110T3 (es) Analogos de sub-unidades de toxina del colera derivados de adn recombinante.
PT625053E (pt) Vacina a base de urease contra a infeccao por helicobacter
ATE181572T1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
KR970009347B1 (en) Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
LU91153I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et de polyoside capsulaire d'Haemophilus influenzae type b.
DE69031351T2 (de) Zubereitungen und behandlungen von pneumonia in tieren
ATE182270T1 (de) Mukosale verabreichung von pneumokokken-antigenen
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
PT787796E (pt) Epitopos protectores de ciclase do adenilo-hemolisina (ac-hly), sua aplicação ao tratamento ou à prevenção das infecções por bordetella
DK230890A (da) Dna-fragment, der koder for et pasteurella multocida-toxin eller for en subsekvens eller analog deraf, ekspressionsvektor, der omfatter dna-fragmentet, mikroorganisme, der udtrykker dette, fremgangsmaade til fremstilling af et pasteurella-multocida-toxin, diagnostisk middel samt anvendelse heraf, vaccine indeholdende et pasteurella-multocida-toxinderivat, anvendelse af pasteurella multocida-t m.m.

Legal Events

Date Code Title Description
FG Patent granted

Owner name: AMGEN INC.

MA Patent expired